Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine Biosciences has the GF Score of 74, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Neurocrine Biosciences
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Neurocrine Biosciences GF Score Related Terms
MEX:NBIX vs VTRS, ELAN, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's GF Score distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's GF Score falls into.
Neurocrine Biosciences (MEX:NBIX) has a GF Score of 74 as of Jul. 18, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Neurocrine Biosciences and its competitors. This is near median its historical median of 73.00. Over the past decade, Neurocrine Biosciences' GF Score has ranged from 73.00 to 73.00.
Is Neurocrine Biosciences' GF Score too high?
Neurocrine Biosciences' current GF Score of 74 is near median its 10-year median of 73.00. Over the past 10 years, this metric has ranged from a low of 73.00 to a high of 73.00. Overall, Neurocrine Biosciences has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' GF Score compare to VTRS and ELAN?
Neurocrine Biosciences' GF Score of 74 can be compared against companies in the Drug Manufacturers industry. Historically, Neurocrine Biosciences' own GF Score has ranged from 73.00 to 73.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current GF Score is 74, which is near median its own 10-year median of 73.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (MEX:NBIX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN3,308.85, compared to a current price of MXN2,970.19 — trading 10.2% below its estimated fair value. The current GF Score is 74, which is near median its 10-year median of 73.00. Neurocrine Biosciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Neurocrine Biosciences (MEX:NBIX), the current GF Score is 74 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (MEX:NBIX) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of MXN2,970.19 is trading 10.2% below its estimated GF Value™ of MXN3,308.85.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for MEX:NBIX:
GF Score: 74 (near median its 10-year median of 73.00)
GF Value™: MXN3,308.85 vs. price of MXN2,970.19 (10.2% below fair value)
No single metric tells the full story. See the MEX:NBIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
74GF Score
Get the complete analysis for MEX:NBIX
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NBIX has been successfully added to your 
